论文部分内容阅读
目的观察尿激酶联合科素亚对IgA肾病的治疗疗效及安全性。方法收集我科2006年1月~2009年12月42例IgA肾病患者,随机分为治疗组和对照组。其中治疗组21例,对照组21例。治疗组给予尿激酶联合科素亚治疗,对照组仅以科素亚治疗。观察12个月后临床评估患者BUN、Scr、和24h尿蛋白定量。结果经过12个月的治疗,治疗组患者的BUN、Scr和24h尿蛋白量均明显下降,与对照组比较,差异有显著性差异(P<0.05)。结论尿激酶联合科素亚能明显降低患者的尿蛋白及保护患者的肾功能。
Objective To observe the curative effect and safety of urokinase combined with cosoxel on IgA nephropathy. Methods A total of 42 IgA nephropathy patients from January 2006 to December 2009 in our department were randomly divided into treatment group and control group. 21 cases in the treatment group and 21 cases in the control group. The treatment group was given urokinase combined with kusuai treatment, the control group only kusuya treatment. The clinical assessment of BUN, Scr, and 24 h urinary protein after 12 months was observed. Results After 12 months’ treatment, the BUN, Scr and 24h urinary protein in the treatment group decreased significantly compared with the control group (P <0.05). Conclusions Urokinase combined with cosoxene can significantly reduce urinary protein in patients and protect the renal function of patients.